Want to see BVS full AI Analyst Report?
EarningsQ2 2026 Earnings Report
BVS Q2 2026 EPS Results
Actual EPS$0.22
Consensus EPS$0.22
Beat/MissBeat by +<$0.01
One Year Ago EPS$0.21
BVS Q2 2026 Revenue Results
Actual Revenue$153.21M
Expected Revenue$155.44M
Beat/MissMissed by -$2.23M
YoY Revenue Growth+3.76%
Earnings Announcement Details
QuarterQ2 2026
Date08/05/2026
TimeBefore Open
Conference CallWednesday, August 5, 2026
BVS Upcoming Earnings
Bioventus's next earnings date is estimated for November 10, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
BVS Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed predominantly positive operational and financial momentum: solid top-line growth (+4% company-wide; +12% in Pain Treatments), margin expansion, strong cash generation and meaningful deleveraging, plus accelerating evidence of traction in strategic growth drivers (PRP, PNS, Ultrasonics, International). Near-term headwinds are mostly transitory and include timing-related revenue shifts (~$2M), modest declines in Surgical, Restorative and International segments, a ~90 bp gross margin drag, higher operating investment and an elevated effective tax rate. Management reaffirmed full-year guidance and expects H2 revenue and cash-flow acceleration, but the announced strategic review introduces a degree of uncertainty. Overall, the positives (durable revenue drivers, profitability, cash generation, deleveraging and confirmed guidance) outweigh the contained near-term challenges.Company Guidance
Overall Financial Performance
Q2 revenue $153M, up 4% YoY; adjusted EBITDA $35M, up >$1M YoY with margin of 23% (expanded 20 bps YoY); adjusted EPS $0.22 vs $0.21 prior year; year-to-date adjusted EPS up 24%.
Pain Treatments Surge (DUROLANE & HA)
Global Pain Treatments revenue $82M, up 12% YoY driven by double-digit volume growth in DUROLANE (single-injection HA), favorable payer mix and commercial execution; PRP and PNS also contributed and are expected to ramp in H2.
Cash Generation and Deleveraging
Cash from operations $20M in Q2; cash on hand $29M; outstanding debt $248M. Repaid $24M in the quarter and $46M YTD; net leverage reduced to below 2x with guidance to be below 1.5x by year-end.
Momentum in Growth Drivers (PRP, PNS, Ultrasonics, International)
PRP: accelerating capital placements and larger/more frequent disposable reorders. PNS: increased surgeon adoption, StimTrial placements with high conversion to permanent TelisMann implants and plan to scale potentially >$100M. Ultrasonics: accelerating disposables growth and new wins with large accounts/IDNs. International: improved execution and pipeline with expectation of strong double-digit growth in H2.
Guidance Reaffirmation and H2 Acceleration
Reaffirmed full-year guidance: revenue $600M–$610M, adjusted EPS $0.75–$0.79, cash from operations $84M–$89M. Management expects YoY revenue growth to increase in H2 by >300 bps versus H1 and cash from operations to approximately double in H2.
Corporate & Culture Recognition
Recognized by U.S. News & World Report as a 'Best Company to Work For,' highlighting talent and culture as strengths supporting execution.
BVS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed